Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for N-acetylcysteine  COVID-19 treatment studies for N-acetylcys..  C19 studies: N-acetylcys..  N-acetylcys..   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality 18% Improvement Relative Risk Ventilation 14% ICU time 20% Hospitalization time 33% Recovery 15% c19early.org/na Taher et al. N-acetylcys.. for COVID-19 RCT LATE Favors N-acetylcysteine Favors control
A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome
Taher et al., Pharmacological Reports, doi:10.1007/s43440-021-00296-2
10 Jun 2021    Source   PDF   Share   Tweet
RCT 92 hospitalized patients, 47 treated with NAC, showing non-significant improvements in outcomes. IRCT20120215009014N355. NAC 40mg/kg/day intravenous for 3 days.
Although the 18% lower mortality is not statistically significant, it is consistent with the significant 22% lower mortality [1‑39%] from meta analysis of the 13 mortality results to date.
risk of death, 17.9% lower, RR 0.82, p = 0.65, treatment 12 of 47 (25.5%), control 14 of 45 (31.1%), NNT 18.
risk of mechanical ventilation, 13.8% lower, RR 0.86, p = 0.67, treatment 18 of 47 (38.3%), control 20 of 45 (44.4%), NNT 16.
ICU time, 20.0% lower, relative time 0.80, p = 0.48, treatment 47, control 45.
hospitalization time, 33.3% lower, relative time 0.67, p = 0.31, treatment 47, control 45.
risk of no recovery, 14.5% lower, RR 0.85, p = 0.41, treatment 25 of 47 (53.2%), control 28 of 45 (62.2%), NNT 11.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Taher et al., 10 Jun 2021, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 6 authors, average treatment delay 7.0 days.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperN-acetylcys..All
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit